GeneDx is trading at $63.44, down 5.51%, with the decline appearing more consistent with biotech-sector pressure than a clearly identified company-specific event.
- Biotech ETF XBI was down 2.08% during the regular session; broader markets were mixed, with the Dow down 1.02%.
- No company-specific announcement explaining the decline was identified. GeneDx’s October 23 study announcement reported positive sequencing results, not an evident negative catalyst.